Relmada Therapeutics, Inc.

RLMD Nasdaq SEC CIK 1553643
Follow Relmada Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$13.9M −37.4% vs same quarter last year
EPS, diluted −$0.12 +60% vs same quarter last year
Operating cash flow −$12.6M −87.2% vs same quarter last year
Operating income −$13.1M −26.8% vs same quarter last year
Net income by quarter
$61.3M
−$17.6M
−$9.9M
−$10.1M
$37.5M
−$19.1M
−$12.9M
−$13.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$200M−$150M−$100M−$50M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25$0
FY24$0
FY23$0
FY22−$157M
FY21−$125.8M
FY20−$59.5M
FY19−$17.3M
FY18−$9M
FY17−$6.3M
FY16−$3M
FY15−$20.8M
FY14-
FY13−$19.9M
FY12−$6.9M
FY11−$874K
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20−$209.9M
FY19−$95.3M
FY18−$6M
FY17−$6.5M
FY16−$13.7M
FY15−$16.3M
FY14-
FY13−$2.2M
FY12-
FY11-